News
-
Adjustment of the Distribution Share - FOPH Circular 733.4-15/1
-
Federal Office of Public Health - New Head of International Affairs Division
-
Products Containing Cannabidiol (CBD) and other Cannabinoids that are not Subject to Narcotics Legislation
-
Swissmedic Receives Grant from the Bill & Melinda Gates Foundation
-
Meeting Highlights from the Pharmacovigilance Risk Assessment Committee 8-11 April 2024
-
COVID-19 Vaccine Strain Updates: Global Regulators Agree on Timing and Data Requirements
-
Decision 9C_126/2023 of 4 March 2024
-
The Federal Council recommends rejecting the "Compulsory Health Insurance Premium Relief Initiative" ("Prämien-Entlastungs-Initiative")
-
The Federal Council recommends rejecting the "Cost Control Initiative" ("Kostenbremse-Initiative")
-
The Federal Council recommends rejecting the popular initiative "For Freedom and Physical Integrity" (Volksinitiative «Für Freiheit und körperliche Unversehrtheit»)
-
Decision C-2370/2021 of 20 March 2024
-
Increased retention fee for medicinal products
-
HPC - Opioids "Boxed Warning"
-
Swissmedic Journal 03/2024
-
Decision 9C_162/2023 of 12 March 2024
-
Decision 9C_637/2023 of 18 March 2024
-
Historic recognition of harm reduction principle at the UN Commission on Narcotic Drugs
-
The Federal Council adopts goals for quality development in health insurance
-
Swissmedic warns against illegal medicinal product "Lemon Bottle" lipolysis solution
-
EU recommendations for 2024/2025 seasonal flu vaccine composition
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024